Table 3:
TP53 Mutation Frequency by Age and Tumor Characteristics
| Tumor Subtypes | |||||
|---|---|---|---|---|---|
| Mutation type | ER− (n=777) | ER+ (n=704) | TNBC (n=439) | Non-TNBC (n=782) | Mean age |
| GOF | 216 (27.8%) | 216 (30.7%) | 126 (28.7%) | 230 (29.4%) | 54.5 |
| LOF | 514 (66.1%) | 424 (60.2%) | 291 (66.3%) | 485 (62%) | 55.0 |
| Unknown | 47 (6%) | 64 (9.1%) | 22 (5%) | 67 (8.6%) | NA |
| p-value | 0.10 | 0.51 | 0.52 | ||
| DNE+ | 288 (37.1%) | 297 (42.2%) | 162 (36.9%) | 317 (40.5%) | 54.5 |
| DNE− | 384 (49.4%) | 285 (40.5%) | 226 (51.5%) | 331 (42.3%) | 55.0 |
| Unknown | 105 (13.5%) | 122 (17.3%) | 51 (11.6%) | 134 (17.1%) | NA |
| p-value | 0.0045 | 0.029 | 0.49 | ||
| Hotspot | 143 (18.4%) | 151 (21.4%) | 81 (18.5%) | 164 (21%) | 53.6 |
| Non-hotspot | 634 (81.6%) | 553 (78.6%) | 358 (81.5%) | 618 (79%) | 55.0 |
| p-value | 0.15 | 0.20 | 0.065 | ||
| Hotspot CpG | 126 (16.2%) | 131 (18.6%) | 75 (17.1%) | 135 (17.3%) | 54.0 |
| Non-hotspot CpG | 651 (83.8%) | 573 (81.4%) | 364 (82.9%) | 647 (82.7%) | 55.0 |
| p-value | 0.24 | 1.0 | 0.30 | ||
n, number; GOF, gain-of-function mutation; LOF, loss-of-function mutation; DNE+, dominant negative activity present; DNE−, no dominant negative activity; ER, Estrogen receptor; TNBC, Triple negative breast cancer